PBYI

PUMA BIOTECHNOLOGY INC

PBYI·74587V107·US·Common Stock·Healthcare - Biotechnology-13D/G

PBYI (PUMA BIOTECHNOLOGY INC) is held by 88 institutional investors as of Q1 2026. Largest holders: BlackRock, Inc. ($23M), RENAISSANCE TECHNOLOGIES LLC ($12.4M), AMERICAN CENTURY COMPANIES INC ($12.2M). Net institutional sentiment: Mixed.

88
Holders
Avg rating(22 Elite)
$168.3M
Total Value
57% (96)
Fund Consensus
47 buying - 36 selling
PBYISmart Money Verdict
View all
Held by 88 funds
22 elite
Who's Trading
ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 27, 2026
InsiderAHAUERBACH ALAN HSell $106KJan 7, 2026
InsiderNFNOUGUES MAXIMO FSell $38KJan 7, 2026
InsiderHMHUNT DOUGLAS MSell $29KJan 7, 2026
InsiderAHAUERBACH ALAN HSell $99KJan 6, 2026
InsiderNFNOUGUES MAXIMO FSell $27KJan 6, 2026
InsiderHMHUNT DOUGLAS MSell $23KJan 6, 2026
InsiderMPMILLER MICHAEL PATRICKSell $97KNov 11, 2025
InsiderCACesano AlessandraSell $91KJul 18, 2025
ActivistBlackRock, Inc.BlackRock, Inc.5.6%Apr 17, 2025
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Decreased
3.6M(-1.2%)$23M0.0%+151.48%
0
Decreased
1.9M(-8.5%)$12.4M0.0%+18.19%
0
Increased
1.9M(+16.1%)$12.2M0.0%+84.01%
32
New
1.8M$11.6M0.0%+28.82%
39
New
1.7M$11.1M0.0%+28.82%
38
Increased
1.5M(+8793.2%)$9.4M0.0%+28.97%
45
Increased
1.4M(+7.2%)$9.2M0.0%+118.03%
30
Increased
1.1M(+1.6%)$7.3M0.0%+69.83%
28
Increased
1M(+2.3%)$6.5M0.0%+5.35%
28
Increased
917,590(+4.6%)$5.9M0.0%+102.56%
28
Increased
800,194(+20.0%)$5.1M0.0%+43.00%
32
Decreased
782,798(-10.6%)$5M0.0%+121.26%
0
Decreased
669,719(-15.7%)$4.3M0.0%+52.74%
0
Increased
641,753(+4.2%)$4.1M0.0%+11.22%
28
Decreased
538,155(-1.8%)$3.4M0.0%+118.97%
0
Increased
534,227(+319.6%)$3.4M0.0%+42.72%
43
Increased
508,182(+18.2%)$3.2M0.0%+2.16%
31
Increased
359,742(+10.1%)$2.3M0.0%+111.66%
29
Decreased
351,235(-7.2%)$2.2M0.0%+157.42%
0
Decreased
347,881(-1.1%)$2.2M0.0%+81.95%
0

Showing 1-20 of 96

1 / 5

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used